← Back to Search

Other

AMG 994 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests two experimental drugs, AMG 994 and AMG 404, in patients with advanced cancer. The goal is to find the safest dose and see how well patients can handle these treatments.

Eligible Conditions
  • Advanced Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Part 2: Dose ExpansionExperimental Treatment2 Interventions
Participants will be administered with the MTD or RP2D of AMG 994 identified in the dose escalation part of the study, in combination with AMG 404.
Group II: Part 1c: Dose ExplorationExperimental Treatment2 Interventions
Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
Group III: Part 1b: Dose ExplorationExperimental Treatment2 Interventions
Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
Group IV: Part 1a: Dose ExplorationExperimental Treatment2 Interventions
Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AMG 994
2021
Completed Phase 1
~20
AMG 404
2020
Completed Phase 1
~230

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor
1,433 Previous Clinical Trials
1,395,131 Total Patients Enrolled
MDStudy DirectorAmgen
971 Previous Clinical Trials
939,303 Total Patients Enrolled

Media Library

AMG 994 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04727554 — Phase 1
Solid Tumors Research Study Groups: Part 2: Dose Expansion, Part 1b: Dose Exploration, Part 1c: Dose Exploration, Part 1a: Dose Exploration
Solid Tumors Clinical Trial 2023: AMG 994 Highlights & Side Effects. Trial Name: NCT04727554 — Phase 1
AMG 994 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04727554 — Phase 1
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top